China has become more cutting edge in terms of innovation rather than being a fast follower and AstraZeneca PLC, the long-time commercial leader there among foreign pharma firms, is determined to partner with the country’s leading R&D pioneers, says Shaun Grady, the UK major’s head of business development operations.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?